vemurafenib (Zelboraf, PLX4032)
Jump to navigation
Jump to search
Indications
- metastatic melanoma (BRAF V600E positive)*
- Erdheim-Chester disease (BRAF V600E positive)
- craniopharyngioma*
* for use in combination with cobimetinib
Adverse effects
- rash
- photosensitivity
- uveitis (10%)[3]
- joint pain
- hair loss
- fatigue
- cutaneous squamous cell carcinoma
Laboratory
Mechanism of action
More general terms
References
- ↑ New Drug Applications http://www.roche.com/med-cor-2011-05-11-e.pdf
- ↑ FDA NEWS RELEASE: Aug. 17, 2011 FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer
- ↑ 3.0 3.1 Guedj M et al. Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib. JAMA Opthalmol 2014 Aug 14 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25125216 <Internet> http://archopht.jamanetwork.com/article.aspx?articleid=1895298
- ↑ ClinicalTrials.gov Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma. https://clinicaltrials.gov/study/NCT03224767